Nilotinib (AMN-107)

Catalog No.S1033

Nilotinib (AMN-107) Chemical Structure

Molecular Weight(MW): 529.52

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 210 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 24 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
Features A selective inhibitor of native and mutant Bcr-Abl.
Targets
Bcr-Abl [1]
(Murine myeloid progenitor cells)
<30 nM
In vitro

Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NHj1e4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMECwNVQ1KM7:TR?= MnvVV2FPT0WU
KU812 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nPUWlEPTB;MD6wNFI1QCEQvF2= M{\3XnNCVkeHUh?=
EM-2 MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMEC0NUDPxE1? M2K1fXNCVkeHUh?=
LAMA-84 Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[2dWlEPTB;MD6wNFQ6KM7:TR?= M2KzWnNCVkeHUh?=
MEG-01 NWG5cWRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjpT29KSzVyPUCuNFA5OjhizszN M4nTVnNCVkeHUh?=
BV-173 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfGdI1KSzVyPUCuNFExQDlizszN NV3tfVJYW0GQR1XS
KASUMI-1 M1nndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrMNollUUN3ME2wMlAzPDF|IN88US=> M2fpPXNCVkeHUh?=
NB7 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLTTWM2OD1yLkGzOFM6KM7:TR?= MmPWV2FPT0WU
BHT-101 MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGyTm9nUUN3ME2wMlY1OjZ|IN88US=> NYHTfHh[W0GQR1XS
CGTH-W-1 Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDQO5dTUUN3ME2wMlY1QDdizszN MVvTRW5ITVJ?
HMV-II M3XWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:1cGg1UUN3ME2wMlc1QDd2IN88US=> NXvDS|hMW0GQR1XS
NKM-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH4TWM2OD1yLkmwNVUh|ryP MoPOV2FPT0WU
LB2241-RCC M3zRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;JR3NKSzVyPUGuNFIzOjhizszN NVrGXFdMW0GQR1XS
NCI-H1703 M17xNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFwMUi4O{DPxE1? M37DR3NCVkeHUh?=
BE-13 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofWTWM2OD1zLkK3OFE3KM7:TR?= NIjtTWpUSU6JRWK=
ACN MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXQZY9ZUUN3ME2xMlU2ODd5IN88US=> NYnHblBIW0GQR1XS
A204 M4LITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwNUeyNFUh|ryP M4fpVHNCVkeHUh?=
HOP-62 NVL2SYptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[0TWM2OD1zLkiyNFc4KM7:TR?= M3vMTHNCVkeHUh?=
H9 NIm2eVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPGU5pKSzVyPUKuO|M4QTNizszN M{jkb3NCVkeHUh?=
HCC1806 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTBZZhGUUN3ME2yMlc1OzJ5IN88US=> NHmySIlUSU6JRWK=
NOS-1 M1XWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y4fWlEPTB;Mj64O|ExOiEQvF2= NYXXOFg5W0GQR1XS
RS4-11 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfWWYJmUUN3ME2yMlkxPjJ|IN88US=> MXzTRW5ITVJ?
JAR MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f5ZmlEPTB;Mj65NlA5PCEQvF2= MYfTRW5ITVJ?
T98G Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzhbG4{UUN3ME2zMlAyOzF|IN88US=> NHW5OIlUSU6JRWK=
NCI-SNU-1 NHHlZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnqWlFKSzVyPUOuOFAxQTJizszN NFvzOoFUSU6JRWK=
SK-MEL-1 M1rWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPTTWM2OD1|LkSzNFI6KM7:TR?= NFjjXVVUSU6JRWK=
L-363 NYLBTXhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTNwNkGxNFch|ryP NWDMcohtW0GQR1XS
SW982 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G1R2lEPTB;Mz62OFE3QSEQvF2= Ml7EV2FPT0WU
HT-1080 NXzNbpRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTNwOUG3O|Uh|ryP NUXQ[HpXW0GQR1XS
G-402 NVPvd4UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rXWmlEPTB;ND6zNVIxOyEQvF2= Mm\0V2FPT0WU
HOS MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTRwOECyPFIh|ryP M{DmS3NCVkeHUh?=
SK-NEP-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fIdmlEPTB;ND64N|E6OSEQvF2= M2LzPHNCVkeHUh?=
HAL-01 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXNVHdKSzVyPUSuPFgzPDJizszN MmPtV2FPT0WU
SBC-1 NIjIPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PyfGlEPTB;ND65NFkxPyEQvF2= NWr6c49LW0GQR1XS
CTV-1 MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTVwNEi5N|gh|ryP NYe0fod5W0GQR1XS
LCLC-103H NYjRVmtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnlcnpKSzVyPUWuO|c1PzFizszN MVHTRW5ITVJ?
RVH-421 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PWemlEPTB;NT63O|U{PiEQvF2= NXfTVY52W0GQR1XS
K-562 M{HLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\6TWM2OD13LkmwN|Yh|ryP MnvWV2FPT0WU
CAL-33 M2W0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nYb2lEPTB;Nj6zNVM2QSEQvF2= NYjXN5pWW0GQR1XS
MDA-MB-361 MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn70TWM2OD14LkOzOlk6KM7:TR?= NYfBcolqW0GQR1XS
IGROV-1 NXX6XYJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GxXGlEPTB;Nj60O|E6OSEQvF2= Mo\4V2FPT0WU
NY NWPvWGEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLDb5RLUUN3ME22MlU{PTl7IN88US=> MmHHV2FPT0WU
Ramos-2G6-4C10 NEm1OWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTZwNk[5N|Eh|ryP MVPTRW5ITVJ?
HuO9 NY\6e2lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjJTWM2OD14LkezPVY1KM7:TR?= M3;Fd3NCVkeHUh?=
MS-1 NG\Nc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrsNJlKSzVyPUeuNVE6PTNizszN M3HydnNCVkeHUh?=
RPMI-8226 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTdwMkiyPFch|ryP NHfESG5USU6JRWK=
HDLM-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PYTmlEPTB;Nz60NFE1QSEQvF2= MkfvV2FPT0WU
D-566MG NEDJfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXTO4F3UUN3ME23MlQ4OTV3IN88US=> MlHEV2FPT0WU
SK-MEL-24 NYHyXWI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTdwNkOzPVIh|ryP NXW3WG5kW0GQR1XS
COLO-679 M3HnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33CcWlEPTB;Nz65PFY4OSEQvF2= NUDjR2o2W0GQR1XS
EW-13 Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjGO5BHUUN3ME24MlMzODV2IN88US=> NGPRVoRUSU6JRWK=
A388 NWHGe|NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrOTWM2OD16LkO4OFgyKM7:TR?= M1nHV3NCVkeHUh?=
UM-UC-3 NGPjNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRThwNEO5OVYh|ryP MnnFV2FPT0WU
NUGC-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRThwNUO1PFIh|ryP MW\TRW5ITVJ?
COLO-668 NV61TmZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRThwNUm0PVEh|ryP M4nqbHNCVkeHUh?=
MOLT-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRThwNkKzOVMh|ryP MVzTRW5ITVJ?
D-423MG MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWzTWM2OD16LkizO|U3KM7:TR?= Mn;sV2FPT0WU
CTB-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljuTWM2OD16Lki3NVI5KM7:TR?= MV3TRW5ITVJ?
BCPAP NFH1[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTlwMEK1OlIh|ryP MmrMV2FPT0WU
GCT M4HhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;aU4twUUN3ME25MlA6QDNzIN88US=> M1HhU3NCVkeHUh?=
ACHN M1;1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LwRmlEPTB;OT6yN|Y{OiEQvF2= NEPrfIhUSU6JRWK=
KYSE-520 Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrk[|BKSzVyPUmuN|M1QDJizszN MVrTRW5ITVJ?
LB771-HNC M1\0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L2bWlEPTB;OT63OlQ6PyEQvF2= MnvjV2FPT0WU
MLMA MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXW[HVWUUN3ME2xNE4xOTN{IN88US=> NWLZbYZEW0GQR1XS
HEC-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:1ZmlEPTB;MUCuNlgxPCEQvF2= M4fTTHNCVkeHUh?=
HL-60 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTFyLk[4OVMh|ryP NHfROndUSU6JRWK=
A101D NXfPV3NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\reGlEPTB;MUCuPFkzOyEQvF2= MV\TRW5ITVJ?
A2058 NHThenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7wWXNKSzVyPUGwMlkzPDVizszN M1fW[nNCVkeHUh?=
KARPAS-45 Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:1V|FKSzVyPUGxMlA3OzVizszN NHKybWhUSU6JRWK=
697 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\NTWM2OD1zMT6yNVAyKM7:TR?= M33VSnNCVkeHUh?=
NCI-N87 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFzLke3N|Eh|ryP MmfRV2FPT0WU
DSH1 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvlN282UUN3ME2xNU44QTV|IN88US=> MXrTRW5ITVJ?
HLE NF3NZ|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnWPIdKSzVyPUGxMlg5OzlizszN NX7Gfms2W0GQR1XS
NCI-H720 NYXkUYJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7TV5pKSzVyPUGyMlY5ODFizszN NFfrfYlUSU6JRWK=
EW-3 NHy1XnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfNPVM4UUN3ME2xNk46OzB5IN88US=> MkXUV2FPT0WU
AGS NVGyeo9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF|LkCzOVEh|ryP M3;pc3NCVkeHUh?=
ES5 M4ThPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXOW|RtUUN3ME2xN{4xPTF{IN88US=> NV7vOYJ7W0GQR1XS
DB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF|LkOyOVYh|ryP MkPVV2FPT0WU
A4-Fuk NXvSRWxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW5[3JKSzVyPUGzMlQyODJizszN MVPTRW5ITVJ?
A427 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;oOlZqUUN3ME2xN{41QTd{IN88US=> NXL4VmdtW0GQR1XS
MN-60 M17adWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljpTWM2OD1zMz61PFQ{KM7:TR?= NVe0XmhFW0GQR1XS
HCC2218 NYLZe4FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTGTWM2OD1zMz61PFU3KM7:TR?= M{fvUnNCVkeHUh?=
MV-4-11 NUf5OldmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF|LkixN|ch|ryP M3\zWHNCVkeHUh?=
GI-1 Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF2LkGxPFQh|ryP NVvKSIhqW0GQR1XS
JVM-3 M373PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSwNo05UUN3ME2xOE4zPjV4IN88US=> MVXTRW5ITVJ?
NCI-H2029 M2\tV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HMcGlEPTB;MUSuNlczPyEQvF2= NHHmWVVUSU6JRWK=
TE-12 NYr6[IR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTz[G5WUUN3ME2xOE43ODR4IN88US=> MlzhV2FPT0WU
WM-115 NVfsdVlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTjdpRKSzVyPUG1MlU3QDNizszN Ml\rV2FPT0WU
BB65-RCC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fyUmlEPTB;MU[uNFI1OSEQvF2= M1HT[XNCVkeHUh?=
NCI-H1693 NELZRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF4LkO4NFIh|ryP NFTtbGdUSU6JRWK=
KARPAS-299 MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PwcWlEPTB;MU[uOlIxOyEQvF2= M1;De3NCVkeHUh?=
UACC-257 NGXPRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XM[mlEPTB;MUeuNFU5OiEQvF2= NUXL[ottW0GQR1XS
RKO MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DEVGlEPTB;MUeuOlQ{OyEQvF2= MULTRW5ITVJ?
HT-29 NXTGRY1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF5Lke4PFkh|ryP M{GxZ3NCVkeHUh?=
ES7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jrdWlEPTB;MUiuNVEzOiEQvF2= MXzTRW5ITVJ?
DEL NW\VRZN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO3S2lKSzVyPUG4MlMyPzJizszN NHLmenhUSU6JRWK=
BT-549 M4T2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LUd2lEPTB;MUiuOFA6OiEQvF2= M2rEOnNCVkeHUh?=
NCI-H1755 NYrVeFV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XqU2lEPTB;MUiuOVczOyEQvF2= MYLTRW5ITVJ?
HCE-T M{DTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF6LkizOFEh|ryP NVvwRYZvW0GQR1XS
LU-139 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfzXXFKSzVyPUG5MlA1PThizszN MWHTRW5ITVJ?
ECC10 NUO4NYNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrxfXlKSzVyPUG5MlI1PzVizszN MmXhV2FPT0WU
769-P MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfXWnRKSzVyPUG5MlY{OzVizszN MX;TRW5ITVJ?
BALL-1 NV34c5JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PDN2lEPTB;MUmuOlc4PSEQvF2= NVnFUllvW0GQR1XS
LXF-289 NWrGXG5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\le2lEPTB;MUmuPFk4QSEQvF2= M3rQT3NCVkeHUh?=
TYK-nu MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S0PGlEPTB;MUmuPVMyPSEQvF2= MmXkV2FPT0WU
NCI-H630 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLtSmtQUUN3ME2xPU46Ozd6IN88US=> MUnTRW5ITVJ?
EW-18 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJyLkO4NFIh|ryP NHTDZ4lUSU6JRWK=
KYSE-150 NHzKZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\kcoxKSzVyPUKwMlcxPDdizszN M4\Qe3NCVkeHUh?=
LOXIMVI MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkX6TWM2OD1{MD63OVg3KM7:TR?= MX7TRW5ITVJ?
HuP-T3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVznNmdRUUN3ME2yNU4xQDV{IN88US=> NWfYe5JWW0GQR1XS
MFE-280 NXHlZ2pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7Bc4N3UUN3ME2yNU42Pjd7IN88US=> Ml7oV2FPT0WU
SK-OV-3 M3m4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vKTmlEPTB;MkGuPFQxQCEQvF2= MkjRV2FPT0WU
QIMR-WIL M3P5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\EZ5ZKSzVyPUKyMlA1PzhizszN NY[zOWJqW0GQR1XS
NCI-H69 NVPUW3ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ{LkSyPVkh|ryP MoHqV2FPT0WU
TE-5 NUDER4hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX4S3BKSzVyPUKyMlQ6PjVizszN MYnTRW5ITVJ?
NCI-H1993 NUXnNIc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvtWWpZUUN3ME2yNk41QTdzIN88US=> NVjWflZ5W0GQR1XS
NCI-H1092 NVSwc4lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ|LkK4OFMh|ryP MWXTRW5ITVJ?
RH-1 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7nNYJOUUN3ME2yN{42OzV5IN88US=> M3zhWHNCVkeHUh?=
DBTRG-05MG MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[2ZWlEPTB;MkOuPFQ4OiEQvF2= NGjPVGpUSU6JRWK=
Mo-T MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDHdFhsUUN3ME2yN{46KM7:TR?= MVfTRW5ITVJ?
HD-MY-Z NVfSZ2NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TmfmlEPTB;MkSuNlM3OiEQvF2= NUjtNnd4W0GQR1XS
NCI-H2342 MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ2Lk[3Olch|ryP M4jLN3NCVkeHUh?=
C32 M{LON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXVTo9KSzVyPUK0Mlk2PzZizszN MWDTRW5ITVJ?
HTC-C3 NVv0cZdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ3LkO1O|ch|ryP NGnXS4tUSU6JRWK=
NCI-H358 Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jjUGlEPTB;MkWuN|k1OyEQvF2= MojiV2FPT0WU
CAL-85-1 M2K5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO0UnhKSzVyPUK1MlQ2PzdizszN M13QUHNCVkeHUh?=
HT-1197 NEW4R2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJ3LkWzNVkh|ryP NUjXT2VZW0GQR1XS
A172 M1nFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTFWIFVUUN3ME2yOU44OTN4IN88US=> M{m5OnNCVkeHUh?=
SW1573 NXjUXHdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHndoFKSzVyPUK1Mlc4QDVizszN NYHydndDW0GQR1XS
EW-24 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ3Lkm2NkDPxE1? M4rwOXNCVkeHUh?=
SK-MEL-2 NH;iW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPaTnM3UUN3ME2yOk4xOzF{IN88US=> Ml;iV2FPT0WU
LU-65 NXnPW|Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn33TWM2OD1{Nj6wOFUzKM7:TR?= MUTTRW5ITVJ?
KMOE-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\aUZdKSzVyPUK2MlA6OTVizszN NGLidplUSU6JRWK=
H-EMC-SS NUPLWFRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJ4LkSxNVQh|ryP MmPOV2FPT0WU
H4 NWH1XZdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\5b4x5UUN3ME2yOk41OjR|IN88US=> MULTRW5ITVJ?
DU-4475 NGnN[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHzTWM2OD1{Nz6xPFczKM7:TR?= M3rtS3NCVkeHUh?=
HCT-116 NUK5dpprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLrN|NsUUN3ME2yO{41OzR7IN88US=> M3OwenNCVkeHUh?=
MSTO-211H MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ5Lk[yOVUh|ryP M2fhd3NCVkeHUh?=
NCI-H292 MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLxXIdsUUN3ME2yO{46PjF5IN88US=> MlXGV2FPT0WU
NCI-H446 NHruR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTRTWM2OD1{OD6yNVA2KM7:TR?= MkHsV2FPT0WU
NCI-H2009 NWjIfIw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTBPZNuUUN3ME2yPU4yPDNzIN88US=> NWL0O2VZW0GQR1XS
MHH-ES-1 NXfRTXlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm1O41SUUN3ME2yPU4{Pjh3IN88US=> MUTTRW5ITVJ?
TI-73 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfVO2lKSzVyPUK5MlQxODFizszN NYXVZnVkW0GQR1XS
NCI-H2228 NV20b297T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3sTWM2OD1{OT60OVgh|ryP NHjq[llUSU6JRWK=
MHH-PREB-1 M3rKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ7LkW1NFUh|ryP NEDzW3ZUSU6JRWK=
ChaGo-K-1 Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHIO2FKSzVyPUK5MlYxQTdizszN MXfTRW5ITVJ?
KY821 Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e5c2lEPTB;MkmuOlQ{OyEQvF2= MX;TRW5ITVJ?
NCI-H209 NXXYd5Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLVeHJKSzVyPUK5Mlg{PjZizszN NG[3T|JUSU6JRWK=
NBsusSR NVXDOlBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF71cnZKSzVyPUK5Mlk6ODRizszN M{DnUXNCVkeHUh?=
NCI-H1304 Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTNyLkW3NVYh|ryP NYm3XpZ2W0GQR1XS
NB14 Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTNzLkC0OFYh|ryP MnLLV2FPT0WU
HCC1419 M2rLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz6TWM2OD1|MT6yOEDPxE1? Mof4V2FPT0WU
KG-1 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnyzTWM2OD1|MT63OFI6KM7:TR?= NIDLV5hUSU6JRWK=
A2780 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXuN|NKSzVyPUOxMlg{PThizszN NGe1SHhUSU6JRWK=
NCI-H28 MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrwb2lKSzVyPUOxMlk5PjFizszN NIO5UJNUSU6JRWK=
C2BBe1 NELTN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTyTWpKSzVyPUOyMlI3OzRizszN MU\TRW5ITVJ?
VA-ES-BJ MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\jS|NXUUN3ME2zNk4{OSEQvF2= NWfFRmN4W0GQR1XS
SBC-5 MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jMd2lEPTB;M{KuPFUyOSEQvF2= M2OxdHNCVkeHUh?=
OVCAR-4 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTN|LkS4OFgh|ryP M4HmdXNCVkeHUh?=
COR-L88 Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTN2LkC3OFEh|ryP NInVWJlUSU6JRWK=
SW954 NVTETXJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{POO2lEPTB;M{SuNFc2OiEQvF2= MmnxV2FPT0WU
COLO-684 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVqwSmtpUUN3ME2zOE4{PDB2IN88US=> M1fQe3NCVkeHUh?=
HCC70 NGHnVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjVZmtUUUN3ME2zOE46PTF2IN88US=> NF\KN2tUSU6JRWK=
NCI-H1770 M37M[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nNV2lEPTB;M{SuPVYyKM7:TR?= M2XpbnNCVkeHUh?=
NCI-H1666 M3uwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33C[WlEPTB;M{WuPFI2OyEQvF2= M4H3b3NCVkeHUh?=
YH-13 M4fxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXlXVNKSzVyPUO1MlkzKM7:TR?= MW\TRW5ITVJ?
DJM-1 M{PrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HIW2lEPTB;M{[uPFA1QSEQvF2= MojwV2FPT0WU
KNS-62 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DadGlEPTB;M{[uPVQ{QCEQvF2= NI\wNHJUSU6JRWK=
SK-MEL-30 NXT5fW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvDepVWUUN3ME2zO{45PzN5IN88US=> MYjTRW5ITVJ?
SJRH30 NH7iUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7UOYI2UUN3ME2zPE44OzRzIN88US=> NETBSYFUSU6JRWK=
GP5d M2e2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv2XpJIUUN3ME2zPE45PjV|IN88US=> M2LnW3NCVkeHUh?=
SW1116 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLGTWM2OD1|OT6yPFA2KM7:TR?= MmLhV2FPT0WU
COLO-800 M3PEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTN7LkO2N|gh|ryP NXTHU5JVW0GQR1XS
RD Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXiWY9KSzVyPUO5MlUzPThizszN MVXTRW5ITVJ?
NCI-SNU-5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;NOWlEPTB;M{muOlkyPiEQvF2= MYDTRW5ITVJ?
HuO-3N1 M{XPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjRXHhKSzVyPUSwMlExQCEQvF2= NHTSXnlUSU6JRWK=
SK-UT-1 NVOwZVd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\yVGlEPTB;NECuOVY4PCEQvF2= MUjTRW5ITVJ?
SK-MEL-3 M2S4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTRyLkW5N|Ih|ryP M{O1OXNCVkeHUh?=
SK-MEL-28 M1S5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7Oe2w4UUN3ME20NE43PDN3IN88US=> MVLTRW5ITVJ?
SCC-4 NV;jTmlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTLZpBFUUN3ME20NU4zOTN5IN88US=> MULTRW5ITVJ?
no-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPnTWM2OD12MT63N|U1KM7:TR?= NHH1e3pUSU6JRWK=
HT-144 NHyzO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS2TWM2OD12Mj6wOVY4KM7:TR?= M1PzfnNCVkeHUh?=
MFM-223 NFjtWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTR{LkSwNkDPxE1? M3KyOnNCVkeHUh?=
ONS-76 NIrnNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4i3cWlEPTB;NEKuPFAyQCEQvF2= M2HkcHNCVkeHUh?=
ES8 NHy3e2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfSNWFKSzVyPUSzMlM3QThizszN NV60bZZtW0GQR1XS
T-24 NInaV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTR|LkSzOlkh|ryP MV7TRW5ITVJ?
GAMG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6zWZpKSzVyPUSzMlQ2OTdizszN NHTsdIRUSU6JRWK=
LU-135 NHy5XVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojITWM2OD12ND6wPVI{KM7:TR?= NWXOPJd[W0GQR1XS
HCC1187 M2KwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr5VGtVUUN3ME20OE45OjZ{IN88US=> NF\GV2pUSU6JRWK=
TE-1 NVy0dGVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTMRpRKSzVyPUS1MlE3PTRizszN MYjTRW5ITVJ?
J-RT3-T3-5 MmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfBTWM2OD12NT60N|E2KM7:TR?= NUThOFFnW0GQR1XS
GI-ME-N NH3Pc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ITWM2OD12NT64PVUzKM7:TR?= NFfEVm5USU6JRWK=
D-392MG MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXBd3ZMUUN3ME20OU46OjV4IN88US=> M33HZXNCVkeHUh?=
KALS-1 NWn0UYY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoizTWM2OD12Nj63NlU4KM7:TR?= Mm\xV2FPT0WU
MMAC-SF M3jTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTEZnpmUUN3ME20Ok46QTV{IN88US=> MUXTRW5ITVJ?
HSC-3 NHO5VHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7rTWM2OD12Nz6zOlA5KM7:TR?= NWG0O3psW0GQR1XS
KM-H2 M{Dzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnCO4dKSzVyPUS3MlYxODdizszN M2HWWXNCVkeHUh?=
LoVo M1HTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS3dIpKSzVyPUS4MlExODJizszN MkLLV2FPT0WU
NCI-H510A M4PyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi3[VZIUUN3ME20PE4yQDdzIN88US=> M{L6XnNCVkeHUh?=
EW-11 M{S2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PPbGlEPTB;NEiuNlM1QCEQvF2= NF3T[VJUSU6JRWK=
HCC2998 M2DWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Lqd2lEPTB;NEiuOlI{PiEQvF2= M4TB[nNCVkeHUh?=
J82 NWLxS2VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHMTWM2OD12OD63NlQzKM7:TR?= NF7TVINUSU6JRWK=
ML-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTR7LkS2NFUh|ryP M3HIUnNCVkeHUh?=
NCI-H2030 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfCTm5ZUUN3ME20PU44OTF5IN88US=> M1\3dHNCVkeHUh?=
NCI-H1792 M3W2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknMTWM2OD12OT64OVE5KM7:TR?= NG[yVodUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: Human primary Schwann and schwannoma cells
  • Concentrations: 1-10 μM
  • Incubation Time: 72 hours
  • Method: Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
  • Formulation: 10% NMP-90% PEG300, PEG300
  • Dosages: 75 mg/kg, 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (50.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 529.52
Formula

C28H22F3N7O

CAS No. 641571-10-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03874858 Not yet recruiting Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 1 2019 Phase 2
NCT03874858 Not yet recruiting Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 1 2019 Phase 2
NCT03784014 Not yet recruiting Soft Tissue Sarcoma Institut National de la Santé Et de la Recherche Médicale France|Commissariat A L''energie Atomique|Institut Bergonié|Plateforme labellisée Inca – Institut Bergonié Bordeaux|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris|CIC-EC 1401/EUCLID March 2019 Phase 3
NCT03784014 Not yet recruiting Soft Tissue Sarcoma Institut National de la Santé Et de la Recherche Médicale France|Commissariat A L''energie Atomique|Institut Bergonié|Plateforme labellisée Inca – Institut Bergonié Bordeaux|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris|CIC-EC 1401/EUCLID March 2019 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use AMN-107 for in vivo studies in mice, can you give me some suggestions about the in vivo formulation?

  • Answer:

    For in vivo study, we recommend to use 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 3mg/ml.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products4

Tags: buy Nilotinib (AMN-107) | Nilotinib (AMN-107) supplier | purchase Nilotinib (AMN-107) | Nilotinib (AMN-107) cost | Nilotinib (AMN-107) manufacturer | order Nilotinib (AMN-107) | Nilotinib (AMN-107) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID